Duality Advisers’s Vertex Pharmaceuticals VRTX Stock Holding History

Duality Advisers’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-3,376	Closed	-$612K	–	699
2021 Q3	$612K	Sell	3,376 -1,920	-36%	-$375K	0.05%	417
2021 Q2	$1.07M	Sell	5,296 -5,074	-49%	-$1.06M	0.09%	328
2021 Q1	$2.23M	Sell	10,370 -5,988	-37%	-$1.32M	0.19%	186
2020 Q4	$3.87M	Buy	16,358 +12,598	+335%	+$2.89M	0.29%	90
2020 Q3	$1.02M	Buy	3,760 +378	+11%	+$104K	0.07%	363
2020 Q2	$982K	Buy	+3,382	New	+$917K	0.09%	253
2020 Q1	–	Sell	-41,254	Closed	-$9.03M	–	318
2019 Q4	$9.03M	Buy	41,254 +38,904	+1,655%	+$7.87M	0.54%	54
2019 Q3	$398K	Buy	+2,350	New	+$416K	0.02%	307

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Duality Advisers's VRTX Position: Q4 2021 in Review

Duality Advisers sold out of Vertex Pharmaceuticals (VRTX) in Q4 2021, closing a stake of 3,376 shares — an estimated $612K sold.

Duality Advisers first reported a position in VRTX in Q3 2019 and held it in 8 quarters. The position peaked at $9.03M in Q4 2019. 1,033 funds tracked by Wall St. Rank hold VRTX as of Q4 2021.

Duality Advisers reported no remaining Vertex Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Duality Advisers sold 3,376 Vertex Pharmaceuticals shares in Q4 2021, an estimated $612K.
Duality Advisers first reported a position in Vertex Pharmaceuticals in Q3 2019 and held it in 8 quarters.
Duality Advisers's Vertex Pharmaceuticals position peaked at $9.03M in Q4 2019.
1,033 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2021.

Based on Duality Advisers's 13F filing for Q4 2021, filed 2 Feb 2022.